Tauopathies with parkinsonism represent a spectrum of disease entities unified by the
pathologic accumulation of hyperphosphorylated tau protein fragments within the central …

ABSTRACT PSP is a pathologically defined neurodegenerative tauopathy with a variety of
clinical presentations including typical Richardson's syndrome and other variant PSP …

Background Progressive supranuclear palsy (PSP) is a neuropathologically defined disease
presenting with a broad spectrum of clinical phenotypes. Objective To identify clinical …

Background: PSP is a neuropathologically defined disease entity. Clinical diagnostic criteria,
published in 1996 by the National Institute of Neurological Disorders and Stroke/Society for …

In a multinational, double‐blind, placebo‐controlled trial (NCT00474058), 287 subjects with
Parkinson's disease (PD) and unsatisfactory early‐morning motor symptom control were …

Objectives: To analyse grey matter changes in early stages of Huntington's disease using
magnetic resonance imaging (MRI) and the technique of voxel based morphometry (VBM) …

It is believed that glycogen synthase kinase‐3 (GSK‐3) hyperphosphorylates tau protein in
progressive supranuclear palsy (PSP). The Tau Restoration on PSP (TAUROS) study was a …

Weight loss is a common phenomenon and an independent prognostic factor in amyotrophic
lateral sclerosis (ALS). Several potential causal mechanisms, including intrinsic …

Objectives Biomarkers for the diagnosis of motoneuron diseases (MND) are urgently
needed to improve the diagnostic pathway, patient stratification and monitoring. The aim of …

PURPOSE: Focal cortical dysplasia (FCD), a frequent cause of partial epilepsy, is often
associated with blurring of the gray–white matter junction in magnetic resonance images …